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 Incremental value to the clinical risk 
assessment
 ABI (ancle brachial index)
<0.9 indicates presence of PAD
>1.3 indicates calcified,
noncompressible arteries
 IMT (carotid intima-media thickness) 
and carotid plaques 
 Increase in carotid IMT values >1mm,
leads to a 2-fold greater risk of acute
MI over 3 years
❶Cardiovascular 
risk assessment 
in people with 
dysglycaemia:
❷Markers that 
may add 
predictive value 
to conventional 
CV risk factors
 LOW
 MODERATE
 HIGH
(DM)
 VERY HIGH 
(DM+≥1CVD risk factor or 
target organ damage)
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The 2012 Joint European Society 
guidelines on CVD prevention
❸Cardiovascular 
risk assessment in 
people with 
dysglycaemia:
MULTIFACTORIAL 
MANAGEMENT
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Molecular basis of
cardiovascular 
disease in diabetes
mellitus
The cardiovascular 
continuum in
diabetes mellitus
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Atheroma from people with DM has more lipid, inflammatory
changes and thrombus than those free from DM.
MECHANISMS 
/CLINICAL 
PRESENTATION 
OF MYOCARDIAL 
ISCHEMIA
ARE THERE 
DIFFERENCESS in 
diabetic patients?
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Ω CAD is more often silent in patients with diabetes, and is
silent in up to 75% of asymptomatic subjects aged 65 years
or older, endothelial dyssfunction is more often in diabetic
patients, seems even more important than atherosclerosis.
Ω Therefore, the evaluation for CAD in asymptomatic
diabetic patients is gaining increasing clinical importance.
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 Up to 60% of myocardial infarctions may be asymptomatic, diagnosed only by 
systematic ECG screening.
 Silent myocardial ischaemia affects 20–35% of DM patients who have additional 
risk factors, and 35–70% of patients with SMI have significant coronary stenoses
whereas, in the others, SMI may result from from endothelial dysfunction and/or  
alteration of coronary microcirculation. 
 Silent myocardial ischaemia may be detected by ECG stress test, myocardial 
scintigraphy or stress echocardiography. 
 Routine screening for CAD in asymptomatic patients is controversial. It is not 
recommended by the ADA, since it does not improve outcomes as long as CV risk 
factors are treated. This position is, however, under debate and the 
characteristics of the patients who should be screened for CAD need to be better 
defined.
 Further evidence is needed to support screening for SMI in all high-risk patients 
with DM. Screening may be performed in patients at a particularly high risk, such 
as those with evidence of PAD or high CAC score or with proteinuria, and in 
people who wish to start a vigorous exercise programme.
Testing an 
asymptomatic 
diabetic patient  
for SCAD
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Clinical Risk 
and Guidelines
Appropriate
Use Criteria
 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging in 2003
(ACC, AHA and ASNC), stated that ‘‘it is not clear that detecting
asymptomatic preclinical CAD with therapeutic intervention will reduce risk
beyond that indicated by risk factor profiling.’’
 However these guidelines do suggest that ‘‘in some asymptomatic
patients, testing may be appropriate when there is a high-risk clinical
situation.’’
 The 2010 ACC/AHA Guideline for Assessment of Cardiovascular Risk in
Asymptomatic adults suggests a severe restriction of the use of stress
imaging, potentially limiting its application to DIABETICS.
 But, an ideal asymptomatic population to discuss the role of MPI are
patients with CHD risk equivalents (diabetes mellitus, other
atherosclerotic disease (peripheral arterial disease, abdominal aortic
aneurysm, carotid artery disease), a 20% 10-year risk of CHD by
Framingham projections, and since resentlu erectile dysfunction).
Patients at high cardiovascular heart disease risk based on standard Adult
Treatment Panel (ATP) III criteria are sutable for CHD detection by
noninvasive imaging modalities.
Clinical Risk 
and 
Guidelines
Appropriate
Use Criteria
STEPWISE APPROACH
1. Patints at high cardiovascular heart disease risk with a
moderately abnormal (100-400) CACS; and
2. Patients with a severely abnormal CACS (>400), in whom
silent myocardial ischemia is known to be prevalent,
are sutable for CHD detection by noninvasive imaging
modalities.
 25% of asymptomatic patients have either a moderate
(15%) or a severe (10%) CACS.
 25% of asymptomatic patients who have at least a
moderate CACS, and 40% of asymptomatic patient who
have at least severe CACS will have abnormal MPI.
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Principles for 
diagnosis of 
CVD in 
diabetic 
patient 
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Principles for 
non-invasive 
diagnosis of 
SCAD
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Recommendations 
for CVD risk 
assessment in 
asymptomatic 
patients 
with Diabetes
Class IIa
In asymptomatic adults with diabetes, 40 years of age and
older, measurement of CAC is reasonable for cardiovascular
risk assessment. (Level of Evidence: B)
Class IIb
Measurement of HbA1C may be considered for
cardiovascular risk assessment in asymptomatic adults with
diabetes. (Level of Evidence: B)
Stress MPI may be considered for advanced cardiovascular
risk assessment in asymptomatic adults with diabetes or
when previous risk assessment testing suggests a high risk
of CHD, such as a CAC score of 400 or greater. (Level of
Evidence: C)
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❶ Role of CAC
in diabetic subjects 
❷ Comparison with 
imaging modalities
❸ Usefulness in 
Motivating Patients
√ The prevalence of CAD on multislice CT in asymptomatic patients
with type 2 diabetes ranges from 60 - 80%.
√ The CAC score is predictive beyond conventional risk factors,
and is an independent prognosticator in diabetic patients.
√  Absent coronary calcium is associated with a low incidence of 
ischaemia on SPECT/PET. 
√  Increasing CAC is associated with an increased risk of an adverse 
cardiac event, and for every increase in CAC the risk is higher in 
diabetics than non-diabetic patients, both in patients with normal, 
and in those with perfusion scan abnormalities.
√ The rationale for CACS as an initial test is that it is most sensitive
for detecting early atherosclerosis, with relatively low radiation
exposure (1-2 mSv).
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PREDICT
(Patients with Renal 
Impairment and Diabetes 
Undergoing Computed 
Tomography) study (589pts)
At a median of 4 years' follow-
up, in a predictive model that 
included CAC score and 
traditional risk factors, the CAC 
score was a highly significant 
independent predictor of CHD 
events or stroke. The model 
found that a doubling in calcium 
score was associated with a 32% 
increase in risk of events. 
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Proportions of patients with an event with increasing time since recruitment into the PREDICT 
study in successive coronary artery calcification score categories (Agatston units).
Comparative analyse of: 
Framingham risk scor, 
UKPDS risk scor, and 
CAC score 
for predicting 
cardiovascular events 
OR = 10.1 for AU score 100 -
400, and 
OR = 58.1 for AU scores 
>1000 
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Ω Subclinical atherosclerosis, measured by coronary
artery calcium (CAC) imaging, has been found
superior to established risk factors for predicting
silent myocardial ischaemia and short-term
outcome.
Ω CAC and myocardial perfusion scintigraphy
findings were synergistic for the prediction of short-
term cardiovascular events.
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CLASS IIb
 1. An exercise ECG may be considered for 
cardiovascular risk assessment in intermediate-
risk asymptomatic adults (including sedentary 
adults considering starting a vigorous exercise 
program), particularly when attention is paid to 
non-ECG markers such as exercise capacity. 
(Level of Evidence: B)
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Exercise ECG 
for Silent 
Myocardial 
Ischemia
 The value of exercise ECG testing to detect silent ischemia
and assess prognosis has been evaluated in a few small
studies of asymptomatic patients with diabetes.
 ECG stress testing has an approximate 50% sensitivity and
80% specificity. The positive predictive value for detecting
CAD using coronary angiography as the gold standard
ranges between 60% and 94% and was higher in men than
women.
 Recommendations for exercise stress testing for risk
assessment do not appear to be different in patients with
diabetes and patients without diabetes.
 The standard exercise test has similar diagnostic
characteristics in diabetic as in nondiabetic patients.
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ROC curves in patients 
with (top) and without 
(bottom) diabetes. 
The AUC is similar 
between the two groups, 
suggesting comparable 
predictive accuracy of 
the exercise test. 
(Chest. 2001;119(5):1576-
1581)
NON INVASIVE 
IMAGING MODALITIES 
TO DETECT ICHAEMIA
SPECT MPI
Appropriate 
indications
I n  a s y m p t o m a t i c  
p a t i e n t s  w i t h o u t  
p r i o r  C A D
At high CVD risk based on Adult Treatment Panel (ATP) III criteria;
At high CVD risk with:
 Moderately abnormal (100-400) CACS; or
 Severely abnormal CACS ([400)
 Only 25% of asymptomatic patients will have a moderate (15%) or a severe (10%)
CACS.
 The limited role of MPI in the asymptomatic patient with risk factors for CAD is
not due to its inaccuracy in risk stratifying but by the very low prevalence of an
abnormal study demonstrating ischemia (5%).
 Routine testing with MPI would result in unnecessary radiation exposure in the
vast majority of patients. However, the likelihood of an abnormal MPI
significantly increases to 25% in asymptomatic patients who have at least a
moderate CACS and to 40% when the CACS is severe.
 The rationale for CACS as an initial test is that it is most sensitive for detecting
early atherosclerosis and with relatively low radiation exposure (1-2 mSv). Based
on CACS results, MPI can be selectively targeted to the small percentage of
asymptomatic patients most likely to have ischemia.
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MPI SPECT
stresors
and 
protocols
SPECT MPI stressors 
 exercise stress (preferred in patients who can exercise, and have 
normal ECG) 
 pharmacologic stress (vasodilators) testing  in patients unable to 
exercise, and/or have abnormal basal ECG
RADIOPHARMACEUTICALS
 technetium (Tc)-99m tracers limit radiation exposure and improve 
overall image quality
 thallium (Tl)-201 in certain specific patients groups.
SPECT MPI stress protocols 
 One-Day Tc-99m Rest/Stress Protocol
 One-Day Tc-99m Stress/Rest Protocol
 Two-Day Stress/Rest Tc99m Protocol
 Two-Day Rest/Stress Tc-99m Protocol
 Stress-Only Tc-99m Protocol
 One-Day Rest Tl-201/Stress Tc-99m Dual Isotope Protocol
 One-Day Tl-201 Stress/Redistribution Protocol
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Perypheral artery 
disease and diabetic 
neuropathy
Ω Reversible 
ischaemia on 
myocardial 
scintigraphy scan in 
the anterior wall.
Ω An occluded 
diagonal artery on 
invasive coronary 
angiogram.
Evidence of Value 
for Risk Assessment 
for Coronary 
Atherosclerosis or 
Ischemia 
to 
Guide Treatment 
or 
Change Patient 
Outcomes
 Abnormal MPI has been found
in 21% to 59% of asymptomatic
diabetic patients. Traditional
and emerging cardiac risk
factors were not associated
with abnormal MPI.
 In the DIAD study, 561 low-risk
asymptomatic patients were
randomized to screening with
adenosine SPECT perfusion
imaging and 562 patients were
randomized to no testing. All
patients had a normal resting
ECG and no prior history of
CAD. Over a mean follow-up of
4.8 years, the cumulative event
rate was 2.9% (0.6% per year).
A, Cumulative incidence of 
CE in 561 participants 
randomized to systematic 
baseline screening with stress 
myocardial perfusion imaging 
(MPI) and 562 participants 
randomized to receive no 
screening. 
B, Cumulative incidence of 
CE according to results of 
stress MPI: normal, small 
defect, moderate or large 
defect, and nonperfusion
abnormality. No cardiac 
events occurred in participants 
who were randomized to, but 
did not complete screening 
MPI. 
JA
M
A
. 20
0
9
;30
1(15):154
7-1555. d
oi:10
.10
0
1/ja
m
a
.20
0
9
.4
76
RESULTS:
There was no difference in event rates between the 2 groups.
In the tested group, those with moderate or large defects had a higher cardiac
event rate than those with a normal scan or small defects.
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Study design
Study results
Study results
Over median 4.4 years 
follow-up, the rate of 
cardiac death/nonfatal 
myocardial infarction (MI) 
was moderate at 2.6%/year 
(cardiac death 0.8%/year) in 
the total cohort but was 
5.7%/year in those with 
ischemia (p<0.001). 
Pharmacologic stress 
predicted a higher cardiac 
event rate (p<0.001) but 
symptoms did not (p=0.55).
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 Clinical risk assessment is key with regards to applying MPI for the
evaluation of asymptomatic individuals, although the exact method of
risk determination remains unclear. (conventional risk models not
applicable?)
 In many settings, a tiered approach to clinical evaluation is
warranted, with risk determination and possibly other testing such as
calcium scoring preceding the performance of MPI.
 Certain subgroups of asymptomatic patients warrant special attention
and consideration for MPI: those with a family history of premature
CHD, CAD risk equivalents (peripheral vascular disease, ED) and
impaired functional capacity, high-risk patients (20% CHD risk for MI or
death within 10 years) constitute a cohort where MPI would be
appropriate.
 The data for the use of MPI in diabetics appears to be reasonable for
high-risk diabetics, including older individuals and those with an
abnormal ECG or an elevated calcium score.
S
tressech
o
card
io
g
rap
h
y
(S
E
)
CLASS III: NO BENEFIT
1. Stress echocardiography is not indicated for
cardiovascular risk assessment in low- or intermediate-
risk asymptomatic adults. (Exercise or pharmacologic
stress echocardiography is primarily used for its role in
advanced cardiac evaluation of symptoms suspected of
representing CHD and/or estimation of prognosis in
patients with known coronary artery disease or the
assessment of patients with known or suspected valvular
heart disease.)
(Level of Evidence: C)
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 Stress echocardiography is the combination of 2D echocardiography
with a physical, pharmacological stress. The diagnostic endpoint for the
detection of myocardial ischemia is the induction of a transient
worsening in regional function during stress.
 Among different stressors of comparable diagnostic and prognostic
accuracy:
 Exercise provides a more physiological environment and additional
physiological data, such as exercise time and workload, changes in heart
rate, blood pressure and ECG. Thus, exercise is the test of choice when
feasible.
 Pharmacological test is preferred when there is already a significant
resting wall motion abnormality:
 Dobutamine for viability assessment, and/or if the patient is unable to
exercise adequately. Until recently, SE relied on inducible wall
thickening abnormalities as a marker of ischaemia, but introduction of
contrast media increased visuability.
 Dipyridamole is the safest and simplest pharmacological stressor and
the most suitable for combined wall motion and coronary flow reserve
assessment.
Non_invasive_tests_in_CAD_evaluation_of_patients[1].pptx
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 There is very little information in the literature on the use of stress
echocardiography in asymptomatic individuals for the purposes of
cardiovascular risk assessment. Accordingly, the Class III (LOE: C)
recommendation for stress echocardiography reflects a lack of
population evidence of this test for risk assessment purposes.
 There are little clinical studies in patients with type 2 diabetes. One
small series compared screening with combined exercise ECG and
dobutamine SE to a no-screening strategy in 141 patients with type 2
diabetes. The series found that the screening strategy was associated
with reduced cardiac events when those with inducible wall motion
abnormalities (21%) underwent revascularization.
 There have been no randomized trials on exercise echocardiography
to suggest that it can be used to motivate lifestyle behavior changes
in asymptomatic adults. One small pilot trial in patients with type 2
diabetes, found no clear indication that an exercise echocardiogram
can be used to motivate asymptomatic adults or guide their therapy.
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 Stress is achieved by the same mechanisms as for other
techniques, exercise or pharmacological. The myocardium is
imaged during the first pass of a bolus of gadolinium during
stress. The normally perfused myocardium enhances with
contrast.
 Reversible ischaemia is visually assessed as a reversible low-
signal defect in the absence of delayed enhancement. An infarct
shows up as an enhancing area as opposed to normal
myocardium, which is black or ‘‘nulled’’ on the delayed
enhancement sequences with gadolinium.
 A recent meta-analysis confirmed a high sensitivity of 89% and a
moderate specificity of 80% for the diagnosis of significant CAD
in a population with a high prevalence of CAD of 57%. The value
of stress CMR in low-prevalence populations is not clear. False
positive tests can be attributed to the presence of artefacts, poor
gating and motion artefacts.
T
h
e B
ritish
 Journ
a
l of R
a
d
iolog
y, S
pecia
l Issue 20
11
A hypoperfusion defect 
in the inferior wall on 
stress MRI. 
(b) No hyperfusion defect 
in the inferior wall on rest 
images. 
(c) Occlusion in the mid-
right coronary artery on 
coronary angiogram.
Stres MRI
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 This is considered to be the gold standard for global 
and regional left ventricular functional analysis. It is 
superior to echocardiography for the following reasons:
(1) the newer sequence, allows good demarcation 
of the endocardial border and blood pool contrast; and
(2) unlike echo, there is no geometric assumption 
and the LVEF can be calculated with reasonable accuracy 
even in distorted ventricles
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 Comparison with SPECT
 A comparison of stress CMR and SPECT in 234 patients in 18 centres 
worldwide was the basis of the MR-IMPACT (magnetic resonance 
imaging for myocardial perfusion assessment in coronary artery 
disease) trial. It showed that stress CMR using 0.1 mmol kg –1 gadolinium 
performed better than SPECT (area under the curve of 0.86 vs 0.67) and 
that stress MR performed better than SPECT in the diagnosis of 
multivessel disease. CMR also consistently detects more subendocardial
defects than SPECT or PET imaging. Nearly half of the segments with 
subendocardial infarcts are missed on SPECT and PET. 
 Comparison with stress echocardiography
 Delayed enhancement CMR has a better negative predictive value than SE, 
particularly in segments with severe dysfunction. Dobutamine
echocardiography has a low sensitivity of 26% in severe left ventricular 
dysfunction, the very segments whose viability assessment needs to be 
accurate. This is because contractility depends on the delivery of adequate 
amount of oxygen to an intact contractile apparatus. In severely 
dysfunctional segments, ionotropic reserve is hampered owing to an 
exhausted coronary flow reserve.
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 Viability imaging on CMR relies 
on the demonstration of scar 
tissue 10–20 min after the 
administration of gadolinium on 
the delayed enhancement. 
 In a study involving 50 
consecutive patients who were 
imaged before and after 
revascularisation, Kim et al 
showed that the extent of the 
infarct on delayed enhancement 
sequences predicted functional 
recovery after revascularisation. 
The extent of the infarct was 
expressed as a percentage of 
the myocardium that enhanced 
with contrast.
 Absence of enhancement and 
enhancement of more than 75% 
of myocardium were the best 
predictors of functional recovery 
79+/-36 days after 
revascularisation.
Enhancement in an 
infarct involving the 
anterior and 
anteroseptal walls of the 
left ventricle on delayed 
enhancement images on 
MRI.
PET
Positron 
emission 
tomography
 PET can be used to assess myocardial perfusion and/or viability.
PET allows acquisition of gated ‘‘stress’’ data during peak hyperemic
blood flow with calculation of a peak stress LVEF.
 RADIOPHARMACEUTICALS:
 rubidium-82 (Rb-82), nitrogen-13 ammonia (N-13 ammonia) for
perfusion,
 F-18 FDG in cardiac PET viability studies.
 STRESSORS:
 Pharmacologic stressors (adenosine, dipyridamole, and
dobutamine have been developed for Rb-82 and N-13 ammonia)
 Exercise stress (is possible, but is challenging due to the short half-
lives of the radiotracers)
PET is not using for CAD screening  in asymptomatic patient
PET 
Perfusion + 
viability +
measuring of the 
absolute 
myocardial blood 
flow
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 Hybrid imaging is a novel technique combining functional and
anatomical aspects, which holds much promise for future clinical
application. The limited evidence available today indicates a higher
diagnostic accuracy, as compared with single techniques.
 CAC scanning may be emerging as the initial test of choice for most
asymptomatic patients. The advent of hybrid SPECT-CT and PET-CT
scanners may signify an important new opportunity for the combined use
of these modalities in the higher-risk asymptomatic patient population.
 With PET/CT systems, customizable CT imaging options include coronary
artery calcium scoring (CACS) and/or CT coronary angiography.
 Hybrid SPECT/CT, PET/CT, customizable CT imaging options include
coronary artery calcium scoring (CACS) and/or CT coronary angiography.
 As performed with SPECT/PET, fusion of CT angiography (CTA) with
perfusion images can create multi-modality images integrating anatomy
and physiology IN THE SAME STUDY.
 Initial reports also point to the prognostic value of hybrid imaging.
R
is
k 
st
ra
ti
fi
ca
ti
o
n
 u
si
n
g
 
is
ch
ae
m
ia
te
st
in
g
20
13 E
S
C
 G
uid
elin
es  on
 th
e m
a
n
a
gem
en
t of  sta
ble coron
a
ry a
rtery d
isea
se
P
ro
g
n
o
st
ic
 a
cc
ur
ac
y 
o
f S
E
 
in
 d
ia
b
et
ic
 p
at
ie
n
ts
C
a
rd
ia
c Im
a
gin
g for R
isk S
tra
tifica
tion
 in
 D
ia
betes,
D
ia
betes ca
re, 20
0
7
Risk 
ASSESSMENT 
AND 
PROGNOSIS 
WITH IMAGING 
MODALITIES IN 
ASYMPTOMATI
C DIABETIC 
PATIENT 
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 Different cardiac imaging modalities provide complementary
information about various aspects of CAD.
 Subclinical atherosclerosis is assessed by coronary calcium
score and coronary CT.
 Coronary CT and MRI of the coronary arteries provide
anatomical information.
 Functional significance of a coronary stenosis is assessed by
stress CMR, radioisotope studies and SE.
 An integrated approach combining anatomical and functional
imaging is important in guiding treatment options and in risk
stratification.
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 There is little information available in the research literature to
suggest the optimal timing to initiate risk assessment in adults.
 There is also limited information to inform decisions about
frequency of risk assessment in persons who are at low or
intermediate risk on initial risk assessment.
 High-risk persons are likely to initiate treatment strategies, and
repeat risk assessment is likely to be a standard component of
patient follow-up.
 More research on the optimal timing to begin and repeat risk
assessment in the asymptomatic patient is warranted.
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